he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源邮箱
上一页:一文掌握癫痫口服宝典
- 2022-05-02范玲教授:母胎医学健康检查中心就是要为孕妇和胎儿开辟“绿色通道”
- 2022-04-28隐源性病症死亡率翻倍
- 2022-04-212013年国际间抗癫痫联合会抗癫痫药使用指南
- 2022-02-14后天早期癫痫病症状能疗法吗
- 癫痫猝死:凶手是谁?
- 癫痫治疗障碍仍难以克服
- 2013国际抗癫痫联合会抗癫痫药用指南
- 抗癫痫药物预防新发癫痫:任重而道远
- UCB的Vimpat癫痫新适应症在美国获批
- FDA批准Aptiom用于治疗患者癫痫发作
- 预测癫痫患者再入院风险
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 治疗癫痫 治疗癫痫偏方大全
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 月经性癫痫患者妊娠期癫痫控制更好
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 黑芝麻的营养价值 吃黑芝麻的好处
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫饮食有哪些禁忌?
- Medpage Today:不同类型的抗癫痫药物更有利
- 心理百科:春节期间小心疾病
- 癫痫怎样治疗?xgrb
- FDA警告怀孕期间使用丙戊酸钠药物
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 羊角病能生孩子吗?
- 癫痫患者手术评估新型工具
- 2015 神经系统疾病诊疗进展
- 综述:癫痫持续状态诊治最新进展
- 明显癫痫病要花多少钱
- 金枪鱼寿司 金枪鱼不一样的吃法
- 男士癫痫遗传吗 癫痫病人怎样生出健康宝宝
- 脑外伤癫痫好不好病患?
- 20120816cctv10健康之中华路:周文静揭秘脑部结构
- 癫痫的治疗方法 西医拔罐治癫痫小方法(2)
- 所致儿童癫痫病的病因有哪些
- 用药犯罪行为大挑战,你能过关吗?
- 小孩子癫痫病怎么科学治疗
- 西兰花的做法中有 凉拌西兰花
- 睡觉时突然发烧一下 新生儿睡觉发烧怎么办
- 如何确实影像无异常的癫痫起源区的呢?
- NeuroImage:纤维球成像可用于癫痫病因进展
- 20130508养生堂:栾国明讲癫痫病的早期呕吐